glp 1 drugs and menopause GLP-1 Weight Loss in Menopause: How HRT Amplifies Results GLP-1 Medications and Menopause Weight

Rather than mimicking GHRH, it activates the second growth hormone release pathway

Main human AOD-9604 treatment timelines Study METAOD004 Participants 36 Route Oral Treatment length 7 days Dose range 9, 27, or 54 mg/day Main lesson Short safety and tolerability study Study METAOD005 Participants 300 Route Oral Treatment length 12 weeks Dose range 1 to 30 mg/day Main lesson Earlier weight-loss trial with a non-linear dose response Study METAOD006 Participants 502 randomized Route Oral Treatment length 24 weeks Dose range 0.25, 0.5, or 1 mg/day Main lesson Primary weight-loss goal was not met The oral milligram doses in these trials cannot be converted into subcutaneous microgram doses

Expert commentary About this Medfyle Read more arrow_downward Hide arrow_upward This content is intended for an international audience of non-UK healthcare professionals

Phase I metabolic reactions introduce a hydrophilic group in the drug molecules where phase II metabolic reactions can take place